AbCellera Biologics Inc [ABCL] stock is trading at $2.62, up 2.34%. An important factor to consider is whether the stock is rising or falling in short-term value. The ABCL shares have gain 5.22% over the last week, with a monthly amount drifted -4.03%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
AbCellera Biologics Inc [NASDAQ: ABCL] stock has seen the most recent analyst activity on August 20, 2024, when The Benchmark Company downgraded its rating to a Hold. Previously, The Benchmark Company upgraded its rating to Buy on February 22, 2024, and kept the price target unchanged to $9. On December 05, 2023, KeyBanc Capital Markets initiated with a Overweight rating and assigned a price target of $6 on the stock. The Benchmark Company downgraded its rating to a Hold. In a note dated December 15, 2022, Goldman initiated an Buy rating and provided a target price of $30 on this stock.
AbCellera Biologics Inc [ABCL] stock has fluctuated between $2.34 and $6.05 over the past year. Currently, Wall Street analysts expect the stock to reach $23.2 within the next 12 months. AbCellera Biologics Inc [NASDAQ: ABCL] shares were valued at $2.62 at the most recent close of the market. An investor can expect a potential return of 785.5% based on the average ABCL price forecast.
Analyzing the ABCL fundamentals
AbCellera Biologics Inc [NASDAQ:ABCL] reported sales of 33.06M for the trailing twelve months, which represents a drop of -27.18%. Gross Profit Margin for this corporation currently stands at -0.86% with Operating Profit Margin at -8.15%, Pretax Profit Margin comes in at -5.41%, and Net Profit Margin reading is -4.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.13 and Total Capital is -0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.57 points at the first support level, and at 2.51 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.65, and for the 2nd resistance point, it is at 2.67.
Ratios To Look Out For
For context, AbCellera Biologics Inc’s Current Ratio is 10.96. On the other hand, the Quick Ratio is 10.96, and the Cash Ratio is 2.46. Considering the valuation of this stock, the price to sales ratio is 23.35, the price to book ratio is 0.69.
